|
|
|
시장보고서
Drug Delivery Technologies: Nucleic Acid Delivery Players, products & prospects to 2018
|
Abstract
The nucleic acid delivery market is maturing with over 1,450 clinical trials
underway worldwide. The majority of these are in early clinical development
(approximately 60%) with just over 3% in Phase III trials. Our analysis
indicates that up to 35 novel nucleic acid products could reach the market
within our forecasting period (2008-2018). However the harsh economic
environment may force companies to place promising drugs on hold as they focus
on lead projects rather than multiple programmes. To date, only a handful of
nucleic acid-based products have been approved for human prescription and
these products rely on delivery technologies in one shape or form. We
estimate the nucleic acid market was worth just over US$80 million globally in
2008.
By 2018 we anticipate the nucleic acid technology market will have matured as
many of the late-stage clinical programmes come to fruition and drug delivery
companies continue to overcome issues surrounding its safety and efficiency.
The development of nucleic acid delivery systems will help to improve
specificity whilst the development of novel polymers and lipopolymer complexes
will help to carry larger DNA payloads in order to target cells and make
multigene targeting a reality. We forecast that nucleic acid products in
development from 11 key companies could generate additional sales of nearly
US$2.3 billion by 2018. These products utilise a range of delivery platforms
including viral to non-viral delivery systems, and cover gene therapies, gene
agents and DNA vaccines for a variety of targets including cancer,
cardiovascular and infectious diseases.
Catalysts for change
Improvements in our understanding into the underlying genetic causes of
disease as well as the uptake of new mechanisms of modulating DNA such as RNA
interference which will help to fuel market growth. The development of a new
generation of DNA vaccines that will provoke strong immunogenic responses and
will help to determine whether this has been a sound investment for the pharma
industry. Launch of the first siRNA-based therapeutics (although progress has
been dampened following the recent termination of Opko Health' s leading eye
treatment at the Phase III development stage). We anticipate companies will
pursue other conditions such as infectious diseases and cancer where robust
preclinical studies have already been performed and where drug delivery
platforms have been adopted rather than the use of naked siRNAs.
This report is part of a major new 4-volume strategic analysis
- VOLUME I CONTROLLED- RELEASE
- VOLUME II NANOTECHNOLOGY
- VOLUME III NUCLEIC ACID DELIVERY
- VOLUME IV TARGETED DELIVERY
Table of Contents
EXECUTIVE SUMMARY & INTRODUCTION
- Overview of delivery technologies for genetic material: past, present &
future
- Leading technology platforms for the delivery of genetic material
- Nucleic acid delivery: motivators & resistors
ADVANCED NUCLEIC ACID DELIVERY TECHNOLOGIES
- Types of nucleic acid-based products under development by the pharma
industry
- Viral vector delivery of nucleic acids
- Bacterial vector delivery of nucleic acids
- Non-viral vector delivery of nucleic acids
- Chemical Technologies
- Physical Technologies
- Current therapeutic applications for the viral and non-viral delivery of
nucleic acids
- Leading nucleic acid-based products in development
- Future commercial applications & opportunities
STRATEGIES OF DRUG DELIVERY COMPANIES
- Leading nucleic acid drug delivery companies
- Strategic developmental & commercialisation partnerships
- Mergers, acquisitions & joint ventures
- Intellectual Property
THE VIRAL AND NON-VIRAL VECTOR DELIVERY MARKET
- Now 2009: Approved nucleic acid product sales
- Future 2018: Novel nucleic acid product sales and Global nucleic acid
product sales
COMPETITOR ANALYSIS
Detailed analysis of leading companies covering:
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Sales forecasts of products utilising the delivery technology
- Competitor ratio analysis
Companies analysed
- Alnylam Pharmaceuticals, Inc.
- AlphaVax, Inc.
- Altea Therapeutics, Inc.
- AP Pharma, Inc.
- ArmaGen Technologies, Inc.
- BioDelivery Sciences International, Inc.
- Calando Pharmaceuticals, Inc.
- Cequent Pharmaceuticals, Inc.
- Copernicus Therapeutics, Inc.
- Diatos SA, Inc.
- DOR BioPharma, Inc
- Expression Genetics, Inc
- Inovio Biomedical Corporation
- MaxCyte, Inc
- Nanotherapeutics, Inc.
- NeoPharm, Inc.
- Novagali Pharma, S.A.
- Oxford Biomedica, Plc.
- PCI Biotech ASA.
- Silence Therapeutics, Plc.
- Targeted Genetics Corporation
- TissueGene, Inc.
- Vical, Inc.
- Zosano Pharma, Inc.
APPENDICIES
- Global nucleic acid approved drug sales 2008-2018
- Global nucleic acid development drug sales 2008-2018
- Key nucleic acid delivery companies by 2018
|
 |
